CTIS2023-505892-56-00进行中（未招募）1 期
ong-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder - NMRA-335140-501
eumora Therapeutics Inc.0 个研究点目标入组 870 人开始时间: 2024年3月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 870
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Completed a previous NMRA-335140 Phase 3 MDD study (NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303) according to the completion definition in the parent study protocol., Signed an informed consent form (ICF) for this study. Note: For participants in the Czech Republic, every participant must have a caregiver participate in the study to help monitor compliance and safety during the study. The caregiver must be in personal contact with the participant at least 5 days a week in severely depressed participants or 2 days a week in moderately depressed participants and accompany the participant to study visits. The caregiver must sign a separate caregiver ICF., Willing to comply with the contraception requirements described in the inclusion criteria of the parent study protocol., Willing to comply with the concomitant medication/therapy restrictions described in the exclusion criteria of the parent study protocol.
排除标准
- •Diagnosed with another Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) disorder that would have been exclusionary in the parent study (eg, personality disorder, bipolar 1 or 2, schizophrenia, any other psychotic disorder, or moderate or severe substance or alcohol use disorder [excluding nicotine])., Considered to be at significant risk of suicide in the judgment of the Investigator. This includes participants who are actively suicidal (eg, any suicide attempts during the parent study) or are at serious suicidal risk as indicated by any current suicidal intent, including a plan, as assessed by the C-SSRS (Since Last Visit version, score of YES on suicidal ideation Item 4 or 5) and/or based on clinical evaluation by the Investigator; or are homicidal, in the opinion of the Investigator., Non-adherent with study medication (took less than or equal to 70% of study drug over any 2-week visit interval) or procedures during the parent study., Experienced treatment emergent adverse events (TEAEs) considered related to the study medication from the parent study and judged by the Investigator to be clinically significant to render the participant ineligible for enrollment., Have an abnormality on ocular examination that would prohibit continued study participation as determined by the Investigator., Use of disallowed concomitant medication or therapy that would have been exclusionary in the parent study, may compromise the safety of the participant, and/or confound the interpretation of protocol assessments., Considered by the Investigator to be inappropriate for any other reason.
研究者
相似试验
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of Lebrikizumabin patients with moderate –to-Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2020-001211-24-LVDermira Inc. a wholly-owned subsidiary of Eli Lilly and Company900
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of Lebrikizumabin patients with moderate –to-Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2020-001211-24-FRDermira Inc. a wholly-owned subsidiary of Eli Lilly and Company900
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of Lebrikizumabin patients with moderate –to-Severe Atopic DermatitisAtopic dermatitisEUCTR2020-001211-24-DEDermira Inc. a wholly-owned subsidiary of Eli Lilly and Company900
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of Lebrikizumabin patients with moderate –to-Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2020-001211-24-LTDermira Inc. a wholly-owned subsidiary of Eli Lilly and Company900
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of Lebrikizumabin patients with moderate –to-Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2020-001211-24-ESDermira Inc. a wholly-owned subsidiary of Eli Lilly and Company900